| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5688380 | Kidney International Reports | 2017 | 9 Pages |
Abstract
The capability to predict 30% decline in eGFR is a novel aspect of this study. TKV was formally qualified, both by FDA and EMA, as a prognostic enrichment biomarker for selecting patients at high risk for a progressive decline in renal function for inclusion in interventional clinical trials.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Ronald D. Perrone, Mohamad-Samer Mouksassi, Klaus Romero, Frank S. Czerwiec, Arlene B. Chapman, Berenice Y. Gitomer, Vicente E. Torres, Dana C. Miskulin, Steve Broadbent, Jean F. Marier,